Carvacrol protects rats against bleomycin-induced lung oxidative stress, inflammation, and fibrosis
- PMID: 38976045
- DOI: 10.1007/s00210-024-03273-7
Carvacrol protects rats against bleomycin-induced lung oxidative stress, inflammation, and fibrosis
Abstract
The main objective of this study was to investigate the potential efficacy of carvacrol (CAR) in mitigating bleomycin (BLM)-induced pulmonary fibrosis (PF). Sixty-six male Wistar rats were assigned into two main groups of 7 and 21 days. They were divided into the subgroups of control, BLM, CAR 80 (only for the 21-day group), and CAR treatment groups. The CAR treatment groups received CAR (20, 40, and 80 mg/kg, orally) for 7 or 21 days after an instillation of BLM (5 mg/kg, intratracheally). Results indicated that BLM significantly increased total cell count in bronchoalveolar lavage fluid and the percentages of neutrophils and lymphocytes, and reduced the percentage of macrophages. CAR dose-dependently decreased total cell count and the percentage of neutrophils and lymphocytes. CAR significantly reduced thiobarbituric acid reactive substances and hydroxyproline levels and elevated the total thiol level and catalase, superoxide dismutase, and glutathione peroxidase activities in BLM-exposed rats. Furthermore, CAR decreased the transforming growth factor-β1, connective transforming growth factor, and tumor necrosis factor-α on days 7 and 21. BLM increased interferon-γ on day 7 but decreased its level on day 21. However, CAR reversed interferon-γ levels on days 7 and 21. Based on histopathological findings, BLM induced inflammation on days 7 and 21, but for induction of fibrosis, 21-day study showed more fibrotic injuries than the 7-day group. CAR showed the improvement of fibrotic injuries. The effect of CAR against BLM-induced pulmonary fibrosis is possibly due to its antioxidant, anti-inflammatory, and antifibrotic activity.
Keywords: Anti-inflammatory; Antifibrotic; Antioxidant; Bleomycin; Carvacrol.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical approval: The study protocol was approved by the Institutional Animal Ethical Committee of AJUMS (IR.AJUMS.REC.1396.256). Consent for publication: The authors confirm their consent for publication. Competing interests: The authors declare no competing interests.
Similar articles
-
Highly Calibrated Relationship Between Bleomycin Concentrations and Facets of the Active Phase Fibrosis in Classical Mouse Bleomycin Model.Int J Mol Sci. 2024 Nov 15;25(22):12300. doi: 10.3390/ijms252212300. Int J Mol Sci. 2024. PMID: 39596365 Free PMC article.
-
Effect of ethyl acetate extract of the whole plant Clerodendrum phlomidis on improving bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) in Rats: In vitro and in vivo research.Int Immunopharmacol. 2025 Jan 3;145:113688. doi: 10.1016/j.intimp.2024.113688. Epub 2024 Dec 6. Int Immunopharmacol. 2025. PMID: 39642567
-
Ginkgo biloba Extract 50 (GBE50) Exerts Antifibrotic and Antioxidant Effects on Pulmonary Fibrosis in Mice by Regulating Nrf2 and TGF-β1/Smad Pathways.Appl Biochem Biotechnol. 2024 Aug;196(8):4807-4822. doi: 10.1007/s12010-023-04755-9. Epub 2023 Nov 16. Appl Biochem Biotechnol. 2024. PMID: 37971580
-
Depressing time: Waiting, melancholia, and the psychoanalytic practice of care.In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5. In: Kirtsoglou E, Simpson B, editors. The Time of Anthropology: Studies of Contemporary Chronopolitics. Abingdon: Routledge; 2020. Chapter 5. PMID: 36137063 Free Books & Documents. Review.
-
Interventions for nail psoriasis.Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD007633. doi: 10.1002/14651858.CD007633.pub2. Cochrane Database Syst Rev. 2013. PMID: 23440816 Free PMC article. Review.
References
-
- Ahmad A, Ansari IA (2021) Carvacrol exhibits chemopreventive potential against cervical cancer cells via caspase-dependent apoptosis and abrogation of cell cycle progression. Anti Cancer Agents Med Chem (Formerly Current Medicinal Chemistry-Anti-Cancer Agents) 21:2224–2235 - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical